Boothbay Fund Management’s Novo Nordisk NVO Stock Holding History

Boothbay Fund Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-116,700	Closed	-$4.29M	–	2516
2026 Q1	$4.29M	Buy	+116,700	New	+$5.53M	0.06%	360
2025 Q4	–	Sell	-54,600	Closed	-$3.03M	–	2242
2025 Q3	$3.03M	Buy	+54,600	New	+$3.2M	0.04%	453
2023 Q2	–	Sell	-71,400	Closed	-$5.68M	–	2141
2023 Q1	$5.68M	Buy	+71,400	New	+$5.06M	0.12%	214

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Boothbay Fund Management's NVO Position: Q2 2026 in Review

Boothbay Fund Management increased its Novo Nordisk (NVO) stake by 204% in Q2 2026, buying an estimated $2.46M and bringing the position to 85,387 shares worth $4.09M. The position accounts for 0.05% of the portfolio, ranked #415.

Boothbay Fund Management first reported a position in NVO in Q1 2020 and has held it in 21 quarters since. The position peaked at $8.28M in Q2 2022. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Boothbay Fund Management held 85,387 shares of Novo Nordisk worth $4.09M as of Q2 2026.
Boothbay Fund Management bought 57,267 Novo Nordisk shares in Q2 2026, an estimated $2.46M.
Novo Nordisk made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #415 holding.
Boothbay Fund Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 21 quarters since.
Boothbay Fund Management's Novo Nordisk position peaked at $8.28M in Q2 2022.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.